Results 361 to 370 of about 185,125 (388)
Some of the next articles are maybe not open access.
Hypomagnesemia and proton-pump inhibitors
Expert Opinion on Drug Safety, 2013Proton pump inhibitors (PPIs) have been linked to clinically symptomatic hypomagnesemia.We searched Medline database in all languages using 'proton-pump inhibitors, magnesium, hypomagnesemia and hypomagnesemic hypoparathyroidism' as search terms and other articles were identified through searches of the files of the authors and reference lists from ...
Laura Gasbarrone +2 more
openaire +3 more sources
Journal of Gastroenterology and Hepatology, 2018
This was a prospective, randomized trial of the efficacy of vonoprazan‐based and proton‐pump inhibitor‐based 7‐day triple regimens with amoxicillin and sitafloxacin as a third‐line therapy for eradicating Helicobacter pylori after failure of ...
Soichiro Sue +6 more
semanticscholar +1 more source
This was a prospective, randomized trial of the efficacy of vonoprazan‐based and proton‐pump inhibitor‐based 7‐day triple regimens with amoxicillin and sitafloxacin as a third‐line therapy for eradicating Helicobacter pylori after failure of ...
Soichiro Sue +6 more
semanticscholar +1 more source
Pharmacogenomics of proton pump inhibitors
Pharmacogenomics, 2004Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are metabolized by cytochrome P450 isoenzyme 2C19 (CYP2C19) in the liver. There are genetic differences that affect the activity of this enzyme. The genotypes of CYP2C19 are classified into three groups: homozygous extensive metabolizer (homEM),
Naohito Shirai +4 more
openaire +3 more sources
British Dental Journal, 2010 Esomeprazole: a proton pump inhibitor
Expert Review of Gastroenterology & Hepatology, 2009Proton pump inhibitors (PPIs) are the most potent inhibitors of gastric acid secretion available, and they are effective for treating all acid-related disorders. Esomeprazole is one of several most recent PPIs that became available to the market in 2001.
Vic Velanovich +2 more
openaire +3 more sources
2017
Guidelines generally recommend proton pump inhibitors (PPIs) over histamine type 2 receptor antagonists when acid suppression is advocated because of a longer duration of action, a superior ability in reducing acid secretion, and the absence of tachyphylaxis with repeated dosing.
Licia Pensabene, Geoffrey P. Davidson
openaire +2 more sources
Guidelines generally recommend proton pump inhibitors (PPIs) over histamine type 2 receptor antagonists when acid suppression is advocated because of a longer duration of action, a superior ability in reducing acid secretion, and the absence of tachyphylaxis with repeated dosing.
Licia Pensabene, Geoffrey P. Davidson
openaire +2 more sources
Proton Pump Inhibitors for Dyspepsia
Digestive Diseases, 2008Proton pump inhibitors are widely used in many upper gastrointestinal disorders. Dyspepsia is a common problem in primary care and endoscopy is neither feasible nor affordable in the majority of patients. <i>Helicobacter pylori</i> eradication has been shown to be effective, but with the declining prevalence of <i>H.
openaire +3 more sources
Saliva Pepsin Detection and Proton Pump Inhibitor Response in Suspected Laryngopharyngeal Reflux
The Laryngoscope, 2018To evaluate the prediction value of saliva pepsin detection for an 8‐week proton pump inhibitor (PPI) response in patients with a Reflux Symptoms Index (RSI) score ≥13, which indicates possible laryngopharyngeal reflux.
Ching‐Ping Wang +6 more
semanticscholar +1 more source
Overuse of proton pump inhibitors
Journal of Clinical Pharmacy and Therapeutics, 2000There have been concerns raised about the potential adverse effects of proton pump inhibitors, especially with long-term use. In particular, their potent action can suppress the features and delay the diagnosis of gastric cancer, while prolonged exposure may hasten the development of gastric carcinoids.To examine the use of proton pump inhibitors in ...
Mark Naunton +3 more
openaire +3 more sources